Erik Domines
Plus aucun poste en cours
Fortune : 174 $ au 30/04/2024
Profil
Erik Domines worked as the General Counsel at Recipharm AB from 2014 to 2018 and at Xbrane Biopharma AB from 2021 to 2023.
He completed his undergraduate degree at the University of Stockholm.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XBRANE BIOPHARMA AB
0,00% | 31/12/2022 | 8 821 ( 0,00% ) | 174 $ | 30/04/2024 |
Anciens postes connus de Erik Domines
| Sociétés | Poste | Fin |
|---|---|---|
| XBRANE BIOPHARMA AB | Conseiller Juridique Général | 01/07/2023 |
| RECIPHARM AB (PUBL) | Conseiller Juridique Général | 31/12/2018 |
Formation de Erik Domines
| University of Stockholm | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XBRANE BIOPHARMA AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Recipharm AB
 Recipharm AB BiotechnologyHealth Technology Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden. | Health Technology |